Nuclear receptors in renal disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 8, 2011, Pages 1061-1067

  Levi, Moshe ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; FXR; Nuclear hormone receptors; PPAR; Renal disease; VDR

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BEZAFIBRATE; CALCITRIOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXERCALCIFEROL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RELATED RECEPTOR; ESTROGEN RELATED RECEPTOR ALPHA; ESTROGEN RELATED RECEPTOR BETA; ESTROGEN RELATED RECEPTOR GAMMA; FARNESOID X RECEPTOR; FENOFIBRATE; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; METFORMIN; OBETICHOLIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; STEROID RECEPTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D RECEPTOR; VITAMIN D RECEPTOR STIMULATING AGENT;

ALBUMINURIA; ATHEROSCLEROSIS; BIOACCUMULATION; BLOOD PRESSURE REGULATION; CATALYSIS; CAUSAL ATTRIBUTION; CELL DAMAGE; CELL DEATH; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; CHRONIC KIDNEY DISEASE; CYTOSOL; DIABETIC NEPHROPATHY; DIET INDUCED OBESITY; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG POTENTIATION; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; FATTY ACID SYNTHESIS; FLUID RETENTION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLOMERULOSCLEROSIS; GLOMERULUS; HEART FAILURE; HENLE LOOP; HEPATITIS; HEYMANN NEPHRITIS; HOMEOSTASIS; HUMAN; HYDROXYLATION; ILEUM; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY DISTAL TUBULE; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; KNOCKOUT MOUSE; LIPID METABOLISM; LIVER FIBROSIS; MESANGIUM CELL; MITOCHONDRION; NEPHRECTOMY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SIDE EFFECT; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; UNSPECIFIED SIDE EFFECT; UPREGULATION; URINE LEVEL; VITAMIN D DEFICIENCY; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION; WEIGHT GAIN;

ANIMALS; HUMANS; KIDNEY DISEASES; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 79958290827     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.04.003     Document Type: Review

References (117)

1. Qian Y., Feldman E., Pennathur S., Kretzler M., Brosius F.C. From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes 2008, 57:1439-1445.
2. Forbes J.M., Coughlan M.T., Cooper M.E. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008, 57:1446-1454.
3. Zhu Y., Usui H.K., Sharma K. Regulation of transforming growth factor beta in diabetic nephropathy: implications for treatment. Semin. Nephrol. 2007, 27:153-160.
4. Gurley S.B., Coffman T.M. The renin-angiotensin system and diabetic nephropathy. Semin. Nephrol. 2007, 27:144-152.
5. Virchow R. Cellular Pathology, as Based upon Physiological and Pathological Histology 1860, Robert M Dewitt, New York. 2nd ed.
6. Kimmelstiel P., Wilson C. Intercapillary lesions in the glomeruli of the kidney. Am. J. Pathol. 1936, 12(83-98):87.
7. Wilens S.L., Elster S.K. The role of lipid deposition in renal arteriolar sclerosis. Am. J. Med. Sci. 1950, 219:183-196. illust.
8. Moorhead J.F., Chan M.K., El-Nahas M., Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982, 2:1309-1311.
9. Weinberg J.M. Lipotoxicity. Kidney Int. 2006, 70:1560-1566.
10. Sun L., Halaihel N., Zhang W., Rogers T., Levi M. Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J. Biol. Chem. 2002, 277:18919-18927.
11. Proctor G., Jiang T., Iwahashi M., Wang Z., Li J., Levi M. Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes 2006, 55:2502-2509.
12. Jiang T., Wang Z., Proctor G., Moskowitz S., Liebman S.E., Rogers T., Lucia M.S., Li J., Levi M. Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J. Biol. Chem. 2005, 280:32317-32325.
13. Wang Z., Jiang T., Li J., Proctor G., McManaman J.L., Lucia S., Chua S., Levi M. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes 2005, 54:2328-2335.
14. Holick M.F. Vitamin D deficiency. N. Engl. J. Med. 2007, 357:266-281.
15. Plum L.A., DeLuca H.F. Vitamin D, disease and therapeutic opportunities. Nat. Rev. Drug Discov. 2010, 9:941-955.
16. Haussler M.R., Haussler C.A., Bartik L., Whitfield G.K., Hsieh J.C., Slater S., Jurutka P.W. Vitamin D receptor: molecular signaling and actions of nutritional ligands in disease prevention. Nutr. Rev. 2008, 66:S98-S112.
17. Ordonez-Moran P., Munoz A. Nuclear receptors: genomic and non-genomic effects converge. Cell Cycle 2009, 8:1675-1680.
18. Tan X., Wen X., Liu Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J. Am. Soc. Nephrol. 2008, 19:1741-1752.
19. Kumar R., Schaefer J., Grande J.P., Roche P.C. Immunolocalization of calcitriol receptor, 24-hydroxylase cytochrome P-450, and calbindin D28k in human kidney. Am. J. Physiol. 1994, 266:F477-F485.
20. Zhang Z., Yuan W., Sun L., Szeto F.L., Wong K.E., Li X., Kong J., Li Y.C. 1,25-Dihydroxyvitamin D3 targeting of NF-kappaB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int. 2007, 72:193-201.
21. Wang Y., Zhou J., Minto A.W., Hack B.K., Alexander J.J., Haas M., Li Y.C., Heilig C.W., Quigg R.J. Altered vitamin D metabolism in type II diabetic mouse glomeruli may provide protection from diabetic nephropathy. Kidney Int. 2006, 70:882-891.
22. Zipitis C.S., Akobeng A.K. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch. Dis. Child. 2008, 93:512-517.
23. Pittas A.G., Lau J., Hu F.B., Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2007, 92:2017-2029.
24. Levin A., Bakris G.L., Molitch M., Smulders M., Tian J., Williams L.A., Andress D.L. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007, 71:31-38.
25. Teng M., Wolf M., Ofsthun M.N., Lazarus J.M., Hernan M.A., Camargo C.A., Thadhani R. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J. Am. Soc. Nephrol. 2005, 16:1115-1125.
26. Zhang Y., Kong J., Deb D.K., Chang A., Li Y.C. Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. J. Am. Soc. Nephrol. 2010, 21:966-973.
27. Freundlich M., Quiroz Y., Zhang Z., Zhang Y., Bravo Y., Weisinger J.R., Li Y.C., Rodriguez-Iturbe B. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int. 2008, 74:1394-1402.
28. Kong J., Qiao G., Zhang Z., Liu S.Q., Li Y.C. Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. Kidney Int. 2008, 74:1577-1581.
29. Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., Cao L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 2002, 110:229-238.
30. Porsti I.H. Expanding targets of vitamin D receptor activation: downregulation of several RAS components in the kidney. Kidney Int. 2008, 74:1371-1373.
31. Yuan W., Pan W., Kong J., Zheng W., Szeto F.L., Wong K.E., Cohen R., Klopot A., Zhang Z., Li Y.C. 1,25-Dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J. Biol. Chem. 2007, 282:29821-29830.
32. Deb D.K., Chen Y., Zhang Z., Zhang Y., Szeto F.L., Wong K.E., Kong J., Li Y.C. 1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-{kappa}B pathway. Am. J. Physiol. Renal Physiol. 2009, 296:F1212-F1218.
33. Li Y., Spataro B.C., Yang J., Dai C., Liu Y. 1,25-Dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int. 2005, 68:1500-1510.
34. Tan X., Li Y., Liu Y. Therapeutic role and potential mechanisms of active vitamin D in renal interstitial fibrosis. J. Steroid Biochem. Mol. Biol. 2007, 103:491-496.
35. Zhang Z., Sun L., Wang Y., Ning G., Minto A.W., Kong J., Quigg R.J., Li Y.C. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int. 2008, 73:163-171.
36. Mizobuchi M., Morrissey J., Finch J.L., Martin D.R., Liapis H., Akizawa T., Slatopolsky E. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J. Am. Soc. Nephrol. 2007, 18:1796-1806.
37. Zhang Z., Zhang Y., Ning G., Deb D.K., Kong J., Li Y.C. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:15896-15901.
38. Deb D.K., Sun T., Wong K.E., Zhang Z., Ning G., Zhang Y., Kong J., Shi H., Chang A., Li Y.C. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int. 2010, 77:1000-1009.
39. Zhang Y., Deb D.K., Kong J., Ning G., Wang Y., Li G., Chen Y., Zhang Z., Strugnell S., Sabbagh Y., Arbeeny C., Li Y.C. Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Am. J. Physiol. Renal Physiol. 2009, 297:F791-F801.
40. Wang X.X., Jiang T., Shen Y., Santamaria H., Solis N., Arbeeny C.M., Levi M. The vitamin D receptor agonist doxercalciferol modulates dietary fat induced renal disease and renal lipid metabolism. Am. J. Physiol. Renal Physiol. 2011.
41. Han S., Li T., Ellis E., Strom S., Chiang J.Y. A novel bile acid-activated vitamin D receptor signaling in human hepatocytes. Mol. Endocrinol. 2010, 24:1151-1164.
42. Makishima M., Lu T.T., Xie W., Whitfield G.K., Domoto H., Evans R.M., Haussler M.R., Mangelsdorf D.J. Vitamin D receptor as an intestinal bile acid sensor. Science 2002, 296:1313-1316.
43. Chow E.C., Maeng H.J., Liu S., Khan A.A., Groothuis G.M., Pang K.S. 1alpha,25-Dihydroxyvitamin D(3) triggered vitamin D receptor and farnesoid X receptor-like effects in rat intestine and liver in vivo. Biopharm. Drug Dispos. 2009, 30:457-475.
44. Schmidt D.R., Holmstrom S.R., Fon Tacer K., Bookout A.L., Kliewer S.A., Mangelsdorf D.J. Regulation of bile acid synthesis by fat-soluble vitamins A and D. J. Biol. Chem. 2010, 285:14486-14494.
45. Branisteanu D.D., Leenaerts P., van Damme B., Bouillon R. Partial prevention of active Heymann nephritis by 1 alpha, 25 dihydroxyvitamin D3. Clin. Exp. Immunol. 1993, 94:412-417.
46. Makibayashi K., Tatematsu M., Hirata M., Fukushima N., Kusano K., Ohashi S., Abe H., Kuze K., Fukatsu A., Kita T., Doi T. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am. J. Pathol. 2001, 158:1733-1741.
47. Migliori M., Giovannini L., Panichi V., Filippi C., Taccola D., Origlia N., Mannari C., Camussi G. Treatment with 1,25-dihydroxyvitamin D3 preserves glomerular slit diaphragm-associated protein expression in experimental glomerulonephritis. Int. J. Immunopathol. Pharmacol. 2005, 18:779-790.
48. Panichi V., Migliori M., Taccola D., Filippi C., De Nisco L., Giovannini L., Palla R., Tetta C., Camussi G. Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int. 2001, 60:87-95.
49. Hirata M., Makibayashi K., Katsumata K., Kusano K., Watanabe T., Fukushima N., Doi T. 22-Oxacalcitriol prevents progressive glomerulosclerosis without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized rats. Nephrol. Dial. Transplant. 2002, 17:2132-2137.
50. Kuhlmann A., Haas C.S., Gross M.L., Reulbach U., Holzinger M., Schwarz U., Ritz E., Amann K. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am. J. Physiol. Renal Physiol. 2004, 286:F526-F533.
51. Schwarz U., Amann K., Orth S.R., Simonaviciene A., Wessels S., Ritz E. Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int. 1998, 53:1696-1705.
52. Xiao H., Shi W., Liu S., Wang W., Zhang B., Zhang Y., Xu L., Liang X., Liang Y. 1,25-Dihydroxyvitamin D(3) prevents puromycin aminonucleoside-induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/Akt-signaling pathway. Am. J. Nephrol. 2009, 30:34-43.
53. Tan X., Li Y., Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J. Am. Soc. Nephrol. 2006, 17:3382-3393.
54. Agarwal R., Acharya M., Tian J., Hippensteel R.L., Melnick J.Z., Qiu P., Williams L., Batlle D. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005, 68:2823-2828.
55. Alborzi P., Patel N.A., Peterson C., Bills J.E., Bekele D.M., Bunaye Z., Light R.P., Agarwal R. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008, 52:249-255.
56. Fishbane S., Chittineni H., Packman M., Dutka P., Ali N., Durie N. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am. J. Kidney Dis. 2009, 54:647-652.
57. Szeto C.C., Chow K.M., Kwan B.C., Chung K.Y., Leung C.B., Li P.K. Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial. Am. J. Kidney Dis. 2008, 51:724-731.
58. Wolf M., Betancourt J., Chang Y., Shah A., Teng M., Tamez H., Gutierrez O., Camargo C.A., Melamed M., Norris K., Stampfer M.J., Powe N.R., Thadhani R. Impact of activated vitamin D and race on survival among hemodialysis patients. J. Am. Soc. Nephrol. 2008, 19:1379-1388.
59. de Zeeuw D., Agarwal R., Amdahl M., Audhya P., Coyne D., Garimella T., Parving H.H., Pritchett Y., Remuzzi G., Ritz E., Andress D. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010, 376:1543-1551.
60. Forman B.M., Goode E., Chen J., Oro A.E., Bradley D.J., Perlmann T., Noonan D.J., Burka L.T., McMorris T., Lamph W.W., Evans R.M., Weinberger C. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995, 81:687-693.
61. Seol W., Choi H.S., Moore D.D. Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. Mol. Endocrinol. 1995, 9:72-85.
62. Makishima M., Okamoto A.Y., Repa J.J., Tu H., Learned R.M., Luk A., Hull M.V., Lustig K.D., Mangelsdorf D.J., Shan B. Identification of a nuclear receptor for bile acids. Science 1999, 284:1362-1365.
63. Parks D.J., Blanchard S.G., Bledsoe R.K., Chandra G., Consler T.G., Kliewer S.A., Stimmel J.B., Willson T.M., Zavacki A.M., Moore D.D., Lehmann J.M. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999, 284:1365-1368.
64. Wang H., Chen J., Hollister K., Sowers L.C., Forman B.M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 1999, 3:543-553.
65. Claudel T., Sturm E., Duez H., Torra I.P., Sirvent A., Kosykh V., Fruchart J.C., Dallongeville J., Hum D.W., Kuipers F., Staels B. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J. Clin. Invest. 2002, 109:961-971.
66. Bookout A.L., Jeong Y., Downes M., Yu R.T., Evans R.M., Mangelsdorf D.J. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 2006, 126:789-799.
67. Thomas C., Pellicciari R., Pruzanski M., Auwerx J., Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discov. 2008, 7:678-693.
68. Lefebvre P., Cariou B., Lien F., Kuipers F., Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 2009, 89:147-191.
69. Fiorucci S., Antonelli E., Rizzo G., Renga B., Mencarelli A., Riccardi L., Orlandi S., Pellicciari R., Morelli A. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 2004, 127:1497-1512.
70. Li Y.T., Swales K.E., Thomas G.J., Warner T.D., Bishop-Bailey D. Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2606-2611.
71. Hartman H.B., Gardell S.J., Petucci C.J., Wang S., Krueger J.A., Evans M.J. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice. J. Lipid Res. 2009, 50:1090-1100.
72. Miyazaki-Anzai S., Levi M., Kratzer A., Ting T.C., Lewis L.B., Miyazaki M. Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/- mice with chronic kidney disease. Circ. Res. 2010, 106:1807-1817.
73. Jiang T., Wang X.X., Scherzer P., Wilson P., Tallman J., Takahashi H., Li J., Iwahashi M., Sutherland E., Arend L., Levi M. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. Diabetes 2007, 56:2485-2493.
74. Wang X.X., Jiang T., Shen Y., Caldas Y., Miyazaki-Anzai S., Santamaria H., Urbanek C., Solis N., Scherzer P., Lewis L., Gonzalez F.J., Adorini L., Pruzanski M., Kopp J.B., Verlander J.W., Levi M. Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes 2010, 59:2916-2927.
75. Wang X.X., Jiang T., Shen Y., Adorini L., Pruzanski M., Gonzalez F.J., Scherzer P., Lewis L., Miyazaki-Anzai S., Levi M. The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. Am. J. Physiol. Renal Physiol. 2009, 297:F1587-F1596.
76. Guan Y., Breyer M.D. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int. 2001, 60:14-30.
77. Ouali F., Djouadi F., Merlet-Benichou C., Bastin J. Dietary lipids regulate beta-oxidation enzyme gene expression in the developing rat kidney. Am. J. Physiol. 1998, 275:F777-F784.
78. Shin S.J., Lim J.H., Chung S., Youn D.Y., Chung H.W., Kim H.W., Lee J.H., Chang Y.S., Park C.W. Peroxisome proliferator-activated receptor-alpha activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats. Hypertens. Res. 2009, 32:835-845.
79. Portilla D., Dai G., Peters J.M., Gonzalez F.J., Crew M.D., Proia A.D. Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure. Am. J. Physiol. Renal Physiol. 2000, 278:F667-F675.
80. Li S., Nagothu K.K., Desai V., Lee T., Branham W., Moland C., Megyesi J.K., Crew M.D., Portilla D. Transgenic expression of proximal tubule peroxisome proliferator-activated receptor-alpha in mice confers protection during acute kidney injury. Kidney Int. 2009, 76:1049-1062.
81. Roman R.J., Ma Y.H., Frohlich B., Markham B. Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats. Hypertension 1993, 21:985-988.
82. Guan Y., Zhang Y., Davis L., Breyer M.D. Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am. J. Physiol. 1997, 273:F1013-F1022.
83. Kono K., Kamijo Y., Hora K., Takahashi K., Higuchi M., Kiyosawa K., Shigematsu H., Gonzalez F.J., Aoyama T. PPAR{alpha} attenuates the proinflammatory response in activated mesangial cells. Am. J. Physiol. Renal Physiol. 2009, 296:F328-F336.
84. Kamijo Y., Hora K., Nakajima T., Kono K., Takahashi K., Ito Y., Higuchi M., Kiyosawa K., Shigematsu H., Gonzalez F.J., Aoyama T. Peroxisome proliferator-activated receptor alpha protects against glomerulonephritis induced by long-term exposure to the plasticizer di-(2-ethylhexyl)phthalate. J. Am. Soc. Nephrol. 2007, 18:176-188.
85. Park C.W., Kim H.W., Ko S.H., Chung H.W., Lim S.W., Yang C.W., Chang Y.S., Sugawara A., Guan Y., Breyer M.D. Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha. Diabetes 2006, 55:885-893.
86. Park C.W., Zhang Y., Zhang X., Wu J., Chen L., Cha D.R., Su D., Hwang M.T., Fan X., Davis L., Striker G., Zheng F., Breyer M., Guan Y. PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int. 2006, 69:1511-1517.
87. Balakumar P., Chakkarwar V.A., Singh M. Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. Mol. Cell. Biochem. 2009, 320:149-162.
88. Calkin A.C., Giunti S., Jandeleit-Dahm K.A., Allen T.J., Cooper M.E., Thomas M.C. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol. Dial. Transplant. 2006, 21:2399-2405.
89. Chen Y.J., Quilley J. Fenofibrate treatment of diabetic rats reduces nitrosative stress, renal cyclooxygenase-2 expression, and enhanced renal prostaglandin release. J. Pharmacol. Exp. Ther. 2008, 324:658-663.
90. Nagai T., Tomizawa T., Nakajima K., Mori M. Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients. J. Atheroscler. Thromb. 2000, 7:91-96.
91. Sacks F.M. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate. Am. J. Cardiol. 2008, 102:34L-40L.
92. Ruan X.Z., Moorhead J.F., Fernando R., Wheeler D.C., Powis S.H., Varghese Z. PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. J. Am. Soc. Nephrol. 2003, 14:593-600.
93. Rigamonti E., Chinetti-Gbaguidi G., Staels B. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1050-1059.
94. Yoshioka S., Nishino H., Shiraki T., Ikeda K., Koike H., Okuno A., Wada M., Fujiwara T., Horikoshi H. Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 1993, 42:75-80.
95. Sarafidis P.A., Bakris G.L. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 2006, 70:1223-1233.
96. Ruan X., Zheng F., Guan Y. PPARs and the kidney in metabolic syndrome. Am. J. Physiol. Renal Physiol. 2008, 294:F1032-F1047.
97. Goyal A., Crook E.D. Thiazolidinediones and progression of renal disease in patients with diabetes. J. Investig. Med. 2006, 54:56-61.
98. Kim M.K., Ko S.H., Baek K.H., Ahn Y.B., Yoon K.H., Kang M.I., Lee K.W., Song K.H. Long-term effects of rosiglitazone on the progressive decline in renal function in patients with type 2 diabetes. Korean J. Intern. Med. 2009, 24:227-232.
99. Guan Y., Hao C., Cha D.R., Rao R., Lu W., Kohan D.E., Magnuson M.A., Redha R., Zhang Y., Breyer M.D. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat. Med. 2005, 11:861-866.
100. Carmona M.C., Louche K., Nibbelink M., Prunet B., Bross A., Desbazeille M., Dacquet C., Renard P., Casteilla L., Penicaud L. Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice. Int. J. Obes. Lond. 2005, 29:864-871.
101. Cha D.R., Zhang X., Zhang Y., Wu J., Su D., Han J.Y., Fang X., Yu B., Breyer M.D., Guan Y. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice. Diabetes 2007, 56:2036-2045.
102. Balakumar P., Arora M.K., Singh M. Emerging role of PPAR ligands in the management of diabetic nephropathy. Pharmacol. Res. 2009, 60:170-173.
103. Wu J., Zhang Y., Wang N., Davis L., Yang G., Wang X., Zhu Y., Breyer M.D., Guan Y. Liver X receptor-alpha mediates cholesterol efflux in glomerular mesangial cells. Am. J. Physiol. Renal Physiol. 2004, 287:F886-F895.
104. Kelly K.J., Wu P., Patterson C.E., Temm C., Dominguez J.H. LOX-1 and inflammation: a new mechanism for renal injury in obesity and diabetes. Am. J. Physiol. Renal Physiol. 2008, 294:F1136-F1145.
105. Letavernier E., Perez J., Joye E., Bellocq A., Fouqueray B., Haymann J.P., Heudes D., Wahli W., Desvergne B., Baud L. Peroxisome proliferator-activated receptor beta/delta exerts a strong protection from ischemic acute renal failure. J. Am. Soc. Nephrol. 2005, 16:2395-2402.
106. Neugarten J., Acharya A., Lei J., Silbiger S. Selective estrogen receptor modulators suppress mesangial cell collagen synthesis. Am. J. Physiol. Renal Physiol. 2000, 279:F309-F318.
107. Potier M., Karl M., Zheng F., Elliot S.J., Striker G.E., Striker L.J. Estrogen-related abnormalities in glomerulosclerosis-prone mice: reduced mesangial cell estrogen receptor expression and prosclerotic response to estrogens. Am. J. Pathol. 2002, 160:1877-1885.
108. Bhat H.K., Hacker H.J., Bannasch P., Thompson E.A., Liehr J.G. Localization of estrogen receptors in interstitial cells of hamster kidney and in estradiol-induced renal tumors as evidence of the mesenchymal origin of this neoplasm. Cancer Res. 1993, 53:5447-5451.
109. Jelinsky S.A., Harris H.A., Brown E.L., Flanagan K., Zhang X., Tunkey C., Lai K., Lane M.V., Simcoe D.K., Evans M.J. Global transcription profiling of estrogen activity: estrogen receptor alpha regulates gene expression in the kidney. Endocrinology 2003, 144:701-710.
110. Pettersson K., Delaunay F., Gustafsson J.A. Estrogen receptor beta acts as a dominant regulator of estrogen signaling. Oncogene 2000, 19:4970-4978.
111. Levin E.R. Plasma membrane estrogen receptors. Trends Endocrinol. Metab. 2009, 20:477-482.
112. Maric C., Sullivan S. Estrogens and the diabetic kidney. Gend. Med. 2008, 5(Suppl A):S103-S113.
113. Seliger S.L., Davis C., Stehman-Breen C. Gender and the progression of renal disease. Curr. Opin. Nephrol. Hypertens. 2001, 10:219-225.
114. Neugarten J., Acharya A., Silbiger S.R. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J. Am. Soc. Nephrol. 2000, 11:319-329.
115. Catanuto P., Doublier S., Lupia E., Fornoni A., Berho M., Karl M., Striker G.E., Xia X., Elliot S. 17 beta-estradiol and tamoxifen upregulate estrogen receptor beta expression and control podocyte signaling pathways in a model of type 2 diabetes. Kidney Int. 2009, 75:1194-1201.
116. Xiao S., Gillespie D.G., Baylis C., Jackson E.K., Dubey R.K. Effects of estradiol and its metabolites on glomerular endothelial nitric oxide synthesis and mesangial cell growth. Hypertension 2001, 37:645-650.
117. Giguere V. Transcriptional control of energy homeostasis by the estrogen-related receptors. Endocr. Rev. 2008, 29:677-696.